strong org growth rais
enough take higher rais estim
upsid organ growth manag deliv
flag favorit name among investor recent
investor sentiment survey stock ytd key
question ahead quarter need deliv drive
stock higher manag answer org growth vs
expect higher org growth ep guidanc rest
year continu execut top coverag univers
see solid momentum growth driver take well next
year reiter outperform rate price target
catalyst libr mitraclip libr remain
key driver view pend fda approv libr potenti
near-term catalyst management also state fda encourag file libr
icgm help boost investor confid pend coverag
expans mitraclip repres anoth catalyst
mgmt focu organ growth execut invest behind
pipelin continu pay remain primarili focus key
growth opportun medic devic diagnost continu
invest maxim impact compani plan manufactur
capac libr alin well op ex support import
program paid bil debt abt strateg flexibl
invest cash improv management continu favor intern growth
program acquisit least
valuat target price unchang base ebitda
multipl unchang estim ntm ebitda month forward
bil unchang risk stabil epd em fx product delay
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global manufactur provid
diversifi healthcar product medic devic equip
area nutrit diagnost vascular intervent
diabet coronari endovascular structur heart
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
addit detail takeaway
nutrit bil mil y/i cc organ vs
ww pediatr nutrit sale bil mil increas organ
reflect unfavor fx vs perform led broad-bas
growth across sever brand well above-market growth sever countri latin
america asia ww adult nutrit sale mil mil increas
organ perform quarter driven strong growth ensur glucerna
diabet specif nutrit brand manag expect nutrit grow mid-singl digit
diagnost bil mil y/i cc organ vs
laboratori diagnost sale bil mil increas organ
led above-market growth ww result continu strong adopt alin
worth note taken share lab rel consist past
year grow mid- high-single-digit low-single-digit growth market
custom buy-in ahead alin architect year transit new
platform compani cite consult solutions-bas sell approach
differenti driver appeal larger provid network help drive
effici lab design staf procedur find encourag ahead
us ramp-up alin product cycl expect begin earnest around
molecular diagnost sale mil mil decreas
organ basi reflect unfavor fx reflect neg impact ngo
purchas pattern africa point diagnost sale mil mil
increas organ sale growth led i-stat handheld system
 ou rapid diagnost sale mil mil decreas
increas organ growth led infecti diseas test develop
market cardio-metabol test ww basi manag expect diagnost
grow high singl digit legaci diagnost busi rapid diagnost
expect grow low-to-mid-singl digit
establish pharma bil mil y/i cc
sale key emerg market india brazil russia china decreas
organ basi reflect unfavor fx em sale decreas
organ sale neg
recent
discontinu suppli agreement context agreement manufactur
third parti end earlier expect result mil hit quarter
manag expect establish pharma grow mid-to high-singl digit
devic bil mil y/i cc
electrophysiolog mil growth led strong perform cardiac
diagnost ablat cathet heart failur mil growth driven uptak
heartmat lvad follow fda approv destin long-term use therapi
late growth structur heart mil led mitraclip grew
ww organ last quarter compani receiv fda
approv expand indic mitraclip treat clinic signific secondari
mr result underli heart failur compani await reimburs
approv expect take month diabet mil sale
increas organ led rapid market uptak freestyl libr
report sale mil organ
quarter
 oper margin slightli better expect bp
bottom line sale net cog lower lower tax rate
partial off-set higher sg deliv upsid ep gross margin
bp estim bp last year
compani rais ep guidanc also
increas full-year organ growth fx expect
neg impact full year report sale in-lin guidanc
compani guid organ sale growth ep fx
expect neg impact sale
sale
sale
ep
estimate
sale
sale
point care
estimate
note insert cardiac monitor icm sale previous report electrophysiolog includ rhythm manag
chang model
decreas sale estim bring ep estim
also made rel minor adjust top-lin project
beyond increas sale estim per year averag also
increas ep estim penni
figur chang model
target price base ebitda multipl estim ntm ebitda
month forward bil risk stabil epd em fx product delay
charl martineau pm univers toronto compani mention price
